Novotel Cannes Montfleury, 25 Avenue Beausejour, 06400 Cannes, France
Please check the event's website for more information
Building on the success of its previous conferences in Xiamen (China) in 2009 and Shanghai (China) in 2011, BioMed Central will host world-renowned experts on the latest research in uncovering the molecular mechanisms underlying age-related neurodegenerative diseases.
Les Diablerets Conference Center, Centre du Village, 1865 Les Diablerets, Switzerland
Please check the conference website for more details
This conference is sponsored by the non-profit Gordon Research Conferences organization and will feature 9 thematic sessions that focus on bioenergetic deficits, activation of inflammatory responses, and white matter metabolism in brain aging and Alzheimer's disease.
The Moller Centre for Continuing Education Limited, Churchill College, Storey's Way, Cambridge CB3 0DE, England
Please check the event's website for more details
Leading neuroscientists from academia and industry involved in genomics, proteomics, diagnostics, imaging and regulatory affairs will discuss the challenges associated with the discovery and validation of biomarkers for autism, Parkinson's disease, Alzheimer's disease, multiple sclerosis and schizophrenia.
The symposium will be sponsored by the Southern Illinois University School of Medicine and the University of Geneva Medical School. Leading scientists will discuss new targets and drugs for treating Alzheimer's disease. More information regarding the event may be found at www.siumed.edu/cme/alzheimer/.
Supported by the Uppsala University, Uppsala University Hospital and the Swedish Research Council, the 2-day conference will present the latest findings on immunotherapy and biomarkers for a variety of neurodegenerative disorders.
Hyatt Regency Jersey City, 2 Exchange Place, Jersey City, NJ 07302
Please check the event's website for further details
This conference is presented by the Alzheimer's Drug Discovery Foundation and will bring together academic and industry researchers to accelerate the development of innovative drugs for the treatment of Alzheimer's disease and related dementias.
It is geared towards scientists, business development and licensing professionals, health management professionals, and venture capitalists.